Positron emission tomography neuroimaging in Parkinson's disease

American Journal of Translational Research

Volumn 3, Issue 4, 2011, Pages 323-341

  Loane, Clare ^a   Politis, Marios ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Parkinson's disease; PET; Positron emission tomography

Indexed keywords

6 FLUORODOPA F 18; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; CARBON 11; OPIATE RECEPTOR;

CHOLINERGIC SYSTEM; DEMENTIA; DENERVATION; DEPRESSION; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; DOPAMINERGIC SYSTEM; FATIGUE; HUMAN; IMPULSE CONTROL DISORDER; MICROGLIA; MOTOR DYSFUNCTION; NEUROIMAGING; NORADRENERGIC SYSTEM; PARKINSON DISEASE; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PSYCHOSIS; REVIEW; SEROTONINERGIC SYSTEM; SLEEP DISORDER; SMELLING;

EID: 80051776203     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Review

References (131)

1. Braak H, Ghebremedhin E, Rüb U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004; 318: 121-34.
2. Kish SJ. Biochemistry of Parkinson's disease: is a brain serotonergic deficiency a characteristic of idiopathic Parkinson's disease? Adv Neurol 2003; 91: 39-49.
3. Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, Furukawa Y. Preferential loss of serotonin markers in caudate versus putamen in Parkinson's disease. Brain 2008; 131: 120-131.
4. Remy P, Doder M, Lees AJ, Turjanski N, Brooks DJ. Depression in Parkinson's disease: loss of dopamine and noradrenaline innervation in the limbic system. Brain 2005; 128: 1314-1322.
5. Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, Piccini P. Staging of serotonergic dysfunction in Parkinson's disease: An in vivo 11C-DASB PET study. Neurobiol Dis 2010; 40: 216-21.
6. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA. Spared caudal brainstem SERT binding in early Parkinson's disease. J Cereb Blood Flow Metab 2008; 8: 441-444.
7. Peppard RF, Martin WR, Carr GD, Grochowski E, Schulzer M, Guttman M, McGeer PL, Phillips AG, Tsui JK, Calne DB. Cerebral glucose metabolism in Parkinson's disease with and without dementia. Arch Neurol 1992;49:1262-8.
8. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010; 133: 3434-43.
9. Burn DJ. Depression in Parkinson's disease. Eur J Neurol 2002; 9 Suppl 3:44-54.
10. O'Sullivan SS, Wu K, Politis M, Lawrence AD, Evans AH, Bose SK, Djamshidian A, Lees AJ, Piccini P. Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive- compulsive behaviours. Brain 2011; 134: 969-78.
11. Nagano-Saito A, Washimi Y, Arahata Y, Iwai K, Kawatsu S, Ito K, Nakamura A, Abe Y, Yamada T, Kato T, Kachi T. Visual hallucination in Parkinson's disease with FDG PET. Mov Disord 2004; 19: 801-6.
12. Wimo A, Jonsson L, Winblad B. An estimate of the worldwide prevalence and direct costs of dementia in 2003. Dement Geriatr Cogn Disord 2006; 21: 175-81.
13. Thomas B, Beal MF. Parkinson's disease. Hum Mol Genet 2007; 16: 183-194.
14. Bower JH, Maraganore DM, McDonnell SK, Rocca WA. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976 -1990. Neurology 1999; 2:1214-20.
15. Tanner CM, Goldman SM. Epidemiology of Parkinson's disease. Neurol Clin 1996; 14: 317-335.
16. Kuzuhara S, Mori H, Izumiyama N, YoshimuraM, Ihara Y. Lewy bodies are ubiquitinated: a light and electron microscopic immunocytochemical study. Acta Neuropathol (Berl) 1988; 75: 345-353.
17. Pollanen MS, Dickson DW, Bergeron C. Pathology and biology of the Lewy body. J Neuropathol Exp Neurol 1993;52:183-191
18. Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983;305:137-8.
19. Vingerhoets FJ, Schulzer M, Calne DB, Snow BJ.Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol 1997; 41: 58-64.
20. Broussolle E, Dentresangle C, Landais P, Garcia- Larrea L, Pollak P, Croisile B, Hibert O, Bonnefoi F, Galy G, Froment JC, Comar D. The relation of putamen and caudate nucleus 18FDopa uptake to motor and cognitive performances in Parkinson's disease. J Neurol Sci 1999; 166: 141-51.
21. Otsuka M, Ichiya Y, Kuwabara Y, Hosokawa S, Sasaki M, Yoshida T, Fukumura T, Masuda K, Kato M. Differences in the reduced 18F-Dopa uptakes of the caudate and the putamen in Parkinson's disease: correlations with the three main symptoms. J Neurol Sci 1996; 136: 169-73.
22. Fearnley JM, Lees AJ. Ageing and Parkinson's disease: substantia nigra regional selectivity. Brain 1991; 114:2283-301.
23. Brück A, Aalto S, Rauhala E, Bergman J, Marttila R, Rinne JO. A follow-up study on 6-[18F] fluoro-L-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord 2009;24:1009-15.
24. Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinson's disease: A longitudinal (18) F-dopa PET studies. Neuroimage 2011; 6: 1463-8.
25. Stoessl AJ. Positron emission tomography in premotor Parkinson's disease. Parkinsonism Relat Disord 2007; 13(suppl 3):S421-S424.
26. de la Fuente-Fernández R, Sossi V, McCormick S, Schulzer M, Ruth TJ, Stoessl AJ. Visualizing vesicular dopamine dynamics in Parkinson's disease. Synapse 2009; 63: 713-6.
27. Lee CS, Samii A, Sossi V, Ruth TJ, Schulzer M, Holden JE, Wudel J, Pal PK, de la Fuente- Fernandez R, Calne DB, Stoessl AJ. In vivo positron emission tomographic evidence for compensatory changes in presynaptic dopaminergic nerve terminals in Parkinson's disease. Ann Neurol 2000; 47: 493-503.
28. Salmon E, Brooks DJ, Leenders KL, Turton DR, Hume SP, Cremer JE, Jones T, Frackowiak RS.A two-compartment description and kinetic procedure for measuring regional cerebral [11C]nomifensine uptake using positron emission tomography. J Cereb Blood Flow Metab 1990; 10:307-16.
29. Frost JJ, Rosier AJ, Reich SG, Smith JS, Ehlers MD, Snyder SH, Ravert HT, Dannals RF. Positron emission tomographic imaging of the dopamine transporter with 11C-WIN 35,428 reveals marked declines in mild Parkinson's disease. Ann Neurol 1993; 34: 423-31.
30. Marié RM, Barré L, Rioux P, Allain P, Lechevalier B, Baron JC. PET imaging of neocortical monoaminergic terminals in Parkinson's disease. J Neural Transm Park Dis Dement Sect 1995; 9: 55-71.
31. Tedroff J, Aquilonius SM, Laihinen A, Rinne U, Hartvig P, Anderson J, Lundqvist H, Haaparanta M, Solin O, Antoni G, Gee AD, Ullin J, Långström B. Striatal kinetics of [11C]-(+)- nomifensine and 6-[18F]fluoro-L-dopa in Parkinson's disease measured with positron emission tomography. Acta Neurol Scand 1990; 81: 24-30.
32. Leenders KL, Salmon EP, Tyrrell P, Perani D, Brooks DJ, Sager H, Jones T, Marsden CD, Frackowiak RS. The nigrostriatal dopaminergic system assessed in vivo by positron emission tomography in healthy volunteer subjects and patients with Parkinson's disease. Arch Neurol 1990; 47: 1290-8.
33. Guttman M, Burkholder J, Kish SJ, Hussey D, Wilson A, DaSilva J, Houle S. 11C]RTI-32 PET studies of the dopamine transporter in early dopa-naive Parkinson's disease: implications for the symptomatic threshold. Neurology 1997; 48: 1578-83.
34. Aquilonius SM. What has PET told us about Parkinson's disease? Acta Neurol Scand Suppl 1991; 136:37-9.
35. Schreckenberger M, Hägele S, Siessmeier T, Buchholz HG, Armbrust-Henrich H, Rösch F, Gründer G, Bartenstein P, Vogt T. The dopamine D2 receptor ligand 18Fdesmethoxyfallypride: an appropriate fluorinated PET tracer for the differential diagnosis of parkinsonism. Eur J Nucl Med Mol Imaging 2004; 31: 1128-35.
36. Rinne JO, Laihinen A, Ruottinen H, Ruotsalainen U, Någren K, Lehikoinen P, Oikonen V, Rinne UK. Increased density of dopamine D2 receptors in the putamen, but not in the caudate nucleus in early Parkinson's disease: a PET study with [11C]raclopride. J Neurol Sci 1995;132:156-161
37. Cropley VL, Fujita M, Bara-Jimenez W, Brown AK, Zhang XY, Sangare J, Herscovitch P, Pike VW, Hallett M, Nathan PJ, Innis RB. Pre- and post-synaptic dopamine imaging and its relation with frontostriatal cognitive function in Parkinson disease: PET studies with [11C] NNC 112 and [18F]FDOPA. Psychiatry Res 2008;163:171-82
38. Pavese N, Evans AH, Tai YF, Hotton G, Brooks DJ, Lees AJ, Piccini P. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006;67:1612-7.
39. Rinne JO, Laihinen A, Rinne UK, Någren K, Bergman J, Ruotsalainen U. PET study on striatal dopamine D2 receptor changes during the progression of early Parkinson's disease. Mov Disord 1993; 8: 134-8.
40. Turjanski N, Lees AJ, Brooks DJ. In vivo studies on striatal dopamine D1 and D2 site binding in L-dopa-treated Parkinson's disease patients with and without dyskinesias. Neurology 1997; 49: 717-23.
41. Antonini A, Schwarz J, Oertel WH, Beer HF, Madeja UD, Leenders KL. [11C]raclopride and positron emission tomography in previously untreated patients with Parkinson's disease: Influence of L-dopa and lisuride therapy on striatal dopamine D2-receptors. Neurology 1994; 44: 1325-9.
42. Antonini A, Schwarz J, Oertel WH, Pogarell O, Leenders KL. Long-term changes of striatal dopamine D2 receptors in patients with Parkinson's disease: a study with positron emission tomography and [11C]raclopride. Mov Disord 1997; 12: 33-8.
43. Antonini A, Vontobel P, Psylla M, Günther I, Maguire PR, Missimer J, Leenders KL. Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson's disease. Arch Neurol 1995; 52: 1183-90.
44. Dentresangle C, Veyre L, Le Bars D, Pierre C, Lavenne F, Pollak P, Guerin J, Froment JC, Brousolle E. Striatal D2 dopamine receptor status in Parkinson's disease: an [18F]dopa and [11C]raclopride PET study. Mov Disord 1999; 14: 1025-30.
45. Brooks DJ, Ibanez V, Sawle GV, Playford ED, Quinn N, Mathias CJ, Lees AJ, Marsden CD, Bannister R, Frackowiak RS. Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11Craclopride and positron emission tomography. Ann Neurol 1992; 31: 184-92.
46. Politis M, Piccini P, Pavese N, Koh SB, Brooks DJ. Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp Neurol 2008; 214: 112-6.
47. Piccini P, Pavese N, Brooks DJ. Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol 2003; 53: 647-53.
48. Sawamoto N, Piccini P, Hotton G, Pavese N, Thielemans K, Brooks DJ. Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. Brain 2008; 131: 1294-302.
49. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Brain serotonin HT1A receptors in Parkinson's disease with and without depression measured by positron emission tomography and 11C-WAY100635. Mov Disord 2000; 15 (Suppl 3): 213.
50. Kerenyi L, Ricaurte GA, Schretlen DJ, McCann U, Varga J, Mathews WB, Ravert HT, Dannals RF, Hilton J, Wong DF, Szabo Z. Positron emission tomography of striatal serotonin transporters in Parkinson disease. Arch Neurol 2003; 60: 1223-9.
51. Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinson's disease patients: a study with 123Ibeta- CIT SPECT. J Nucl Med 2003; 44: 870- 876.
52. Tanaka H, Kannari K, Maeda T, Tomiyama M, Suda T, Matsunaga M. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999; 10: 631-4.
53. Maeda T, Nagata K, Yoshida Y, Kannari K. Serotonergic hyperinnervationinto the dopaminergic denervated striatum compensates for dopamine conversion from exogenously administered L-DOPA. Brain Res 2005; 1046:230-3.
54. Bohnen NI, Albin RL, Koeppe RA; Kannari K. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006; 26: 1198-1212.
55. Asahina M, Suhara T, Shinotoh H, Inoue O, Suzuki K, Hattori T. Brain muscarinic receptors in progressive supranuclear palsy and Parkinson's disease: a positron emission tomographic study. J Neurol Neurosurg Psychiatry 1998; 65: 155-63.
56. Koepp MJ, Duncan JS. PET: opiate neuroreceptor mapping. Adv Neurol 2000; 83: 145- 56.
57. Haber SN, Watson SJ. The comparative distribution of enkephalin, dynorphin and substance P in the human globus pallidus and basal forebrain. Neuroscience 1985; 14: 1011-24.
58. Fernandez A, de Ceballos ML, Jenner P, Marsden CD. Neurotensin, substance P, delta and mu opioid receptors are decreased in basal ganglia of Parkinson's disease patients. Neuroscience 1994; 61: 73-9.
59. Ding YS, Lin KS, Garza V, Carter P, Alexoff D, Logan J, Shea C, Xu Y, King P. Evaluation of a new norepinephrine transporter PET ligand in baboons, both in brain and peripheral organs. Synapse 2003 Dec 15; 50(4):345-52.
60. Ding YS, Fowler J. New-generation radiotracers for nAChR and NET. Nucl Med Biol 2005; 32: 707-18.
61. Ouchi Y, Yoshikawa E, Sekine Y, Futatsubashi M, Kanno T, Ogusu T, Torizuka T. Microglial activation and dopamine terminal loss in early Parkinson's disease. Ann Neurol 2005;57:168- 75.
62. Ouchi Y, Yagi S, Yokokura M, Sakamoto M. Neuroinflammation in the living brain of Park inson's disease. Parkinsonism Relat Disord 2009; 15 Suppl 3:S200-4.
63. Gerhard A, Pavese N, Hotton G, Turkheimer F, Es M, Hammers A, Eggert K, Oertel W, Banati RB, Brooks DJ. In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiol Dis 2006; 21: 404-12.
64. Puñal-Riobóo J, Serena-Puig A, Varela-Lema L, Alvarez-Páez AM, Ruano-Ravina A. Clinical utility of (18)F-DOPA-PET in movement disorders. A systematic review].Rev Esp Med Nucl 2009; 28: 106-13.
65. Burn DJ, Brooks DJ. Nigral dysfunction in druginduced parkinsonism: an 18F-dopa PET study. Neurology 1993; 43: 552-6.
66. Otsuka M, Ichiya Y, Hosokawa S, Kuwabara Y, Tahara T, Fukumura T, Kato M, Masuda K, Goto I. Striatal blood flow, glucose metabolism and 18F-dopa uptake: difference in Parkinson's disease and atypical parkinsonism. J Neurol Neurosurg Psychiatry 1991; 54: 898- 904.
67. Sawle GV, Leenders KL, Brooks DJ, Harwood G, Lees AJ, Frackowiak RS, Marsden CD. Dopa -responsive dystonia: [18F]dopa positron emission tomography. Ann Neurol 1991; 30: 4 -30.
68. Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss WD. Differentiating multiple system atrophy from Parkinson's disease: contribution of striatal and midbrain MRI volumetry and multitracer PET imaging. J Neurol Neurosurg Psychiatry 2002; 73: 517-23.
69. Eidelberg D, Takikawa S, Moeller JR, Dhawan V, Redington K, Chaly T, Robeson W, Dahl JR, Margouleff D, Fazzini E, Przedborski S, Fahn S Striatal hypometabolism distinguishes striatonigral degeneration from Parkinson's disease. Ann Neurol 1993; 33: 518-27.
70. Pierot L, Desnos C, Blin J, Raisman R, Scherman D, Javoy-Agid F, Ruberg M, Agid Y. D1 and D2-type dopamine receptors in patients with Parkinson's disease and progressive supranuclear palsy. J Neurol Sci 1988; 86: 291-306.
71. Landwehrmeyer B, Palacios JM. Alterations of neurotransmitter receptors and neurotransmitter transporters in progressive supranuclear palsy. J Neural Transm Suppl 1994; 42:229-46
72. Joyce JN, Ryoo HL, Beach TB, Caviness JN, Stacy M, Gurevich EV, Reiser M, Adler CH. Loss of response to levodopa in Parkinson's disease and co-occurrence with dementia: role of D3 and not D2 receptors. Brain Res 2002; 955: 38-52.
73. Hilker R, Schweitzer K, Coburger S; Ghaemi M, Weisenbach S, Jacobs AH, Rudolf J, Herholz K, Heiss WD. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 2005; 62: 378-382.
74. Panzacchi A, Moresco RM, Garibotto V; Antonini A, Gobbo C, Isaias IU, Goldwurm S, Bonaldi L, Carpinelli A, Pezzoli G, Fazio F, Perani D. A voxel-based PET study of dopamine transporters in Parkinson's disease: relevance of age at onset. Neurobiol Dis 2008; 31: 102-109.
75. Bohnen NI, Kaufer DI, Hendrickson R, Ivanco LS, Lopresti BJ, Constantine GM, Mathis ChA, Davis JG, Moore RY, Dekosky ST. Cognitive correlates of cortical cholinergic denervation in Parkinson's disease and parkinsonian dementia. J Neurol 2006; 253: 242-247.
76. Piccini P, Morrish PK, Turjanski N, Sawle GV, Burn DJ, Weeks RA, Mark MH, Maraganore DM, Lees AJ, Brooks DJ. Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol 1997; 41: 222-9.
77. Piccini P, Burn DJ, Ceravolo R, Maraganore D, Brooks DJ. The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol 1999; 45:577-82.
78. Khan NL, Jain S, Lynch JM, Pavese N, Abou-Sleiman P, Holton JL, Healy DG, Gilks WP, Sweeney MG, Ganguly M, Gibbons V, Gandhi S, Vaughan J, Eunson LH, Katzenschlager R, Gayton J, Lennox G, Revesz T, Nicholl D, Bhatia KP, Quinn N, Brooks D, Lees AJ, Davis MB, Piccini P, Singleton AB, Wood NW. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain 2005; 128: 2786-96.
79. Samii A, Markopoulou K, Wszolek ZK, Sossi V, Dobko T, Mak E, Calne DB, Stoessl AJ. PET studies of parkinsonism associated with mutation in the alpha-synuclein gene. Neurology 1999; 53: 2097-102.
80. Adams JR, van Netten H, Schulzer M, Mak E, Mckenzie J, Strongosky A, Sossi V, Ruth TJ, Lee CS, Farrer M, Gasser T, Uitti RJ, Calne DB, Wszolek ZK, Stoessl AJ. PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain 2005; 128: 2777-85.
81. Khan NL, Brooks DJ, Pavese N, Sweeney MG, Wood NW, Lees AJ, Piccini P. Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain 2002; 125: 2248-56.
82. Scherfler C, Khan NL, Pavese N, Eunson L, Graham E, Lees AJ, Quinn NP, Wood NW, Brooks DJ, Piccini PP. Striatal and cortical preand postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain 2004; 127: 1332-42.
83. Hernandez DG, Paisán-Ruíz C, McInerney-Leo A, Jain S, Meyer-Lindenberg A, Evans EW, Berman KF, Johnson J, Auburger G, Schäffer AA, Lopez GJ, Nussbaum RL, Singleton AB. Clinical and positron emission tomography of Parkinson's disease caused by LRRK2. Ann Neurol 2005; 57: 453-456.
84. Hering R, Strauss KM, Tao X, Bauer A, Woitalla D, Mietz EM, Petrovic S, Bauer P, Schaible W, Müller T, Schöls L, Klein C, Berg D, Meyer PT, Schulz JB, Wollnik B, Tong L, Krüger R, Riess O. Novel homozygous p.E64D mutation in DJ1 in early onset Parkinson disease (PARK7). Hum Mutat 2004; 24: 321-329.
85. Ribeiro MJ, Thobois S, Lohmann E, du Montcel ST, Lesage S, Pelissolo A, Dubois B, Mallet L, Pollak P, Agid Y, Broussolle E, Brice A, Remy P; French Parkinson's Disease Genetics Study Group. A multitracer dopaminergic PET study of young-onset parkinsonian patients with and without parkin gene mutations. J Nucl Med 2009; 50: 1244-50.
86. Pavese N, Khan NL, Scherfler C, Cohen L, Brooks DJ, Wood NW, Bhatia KP, Quinn NP, Lees AJ, Piccini P. Nigrostriatal dysfunction in homozygous and heterozygous parkin gene carriers: an 18F-dopa PET progression study. Mov Disord 2009:2260-6.
87. Pavese N, Moore RY, Scherfler C, Khan NL, Hotton G, Quinn NP, Bhatia KP, Wood NW, Brooks DJ, Lees AJ, Piccini P. In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol 2010; 222: 120-4.
88. Scherfler C, Khan NL, Pavese N, Lees AJ, Quinn NP, Brooks DJ, Piccini PP.Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. Mov Disord 2006; 21: 783-8.
89. Morrish PK, Rakshi JS, Bailey DL, Sawle GV, Brooks DJ. Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. J Neurol Neurosurg Psychiatry 1998; 64: 314-9.
90. Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE. A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000; 342: 1484-91.
91. de la Fuente-Fernández R, Pal PK, Vingerhoets FJ, Kishore A, Schulzer M, Mak EK, Ruth TJ, Snow BJ, Calne DB, Stoessl AJ. Evidence for impaired presynaptic dopamine function in parkinsonian patients with motor fluctuations. J Neural Transm 2000; 107: 49-57.
92. Troiano AR, de la Fuente-Fernandez R, Sossi V, Schulzer M, Mak E, Ruth TJ, Stoessl AJ. PET demonstrates reduced dopamine transporter expression in PD with dyskinesias. Neurology 2009; 72: 1211-6.
93. Kishore A, De la Fuente-Fernandez R, Snow BJ, Schulzer M, Mak E, Huser J, Stoessl AJ, Calne DB. Levodopa-induced dyskinesias in idiopathic Parkinsonism (IP): a simultaneous PET study of dopamine D1 and D2 receptors. Neurology 1997; 48: A327.
94. Torstenson R, Hartvig P, Långström B, Westerberg G, Tedroff J. Differential effects of levodopa on dopaminergic function in early and advanced Parkinson's disease. Ann Neurol 1997; 41: 334-40.
95. Whone AL, Rabiner EA, Arahata Y, Luthra SK, Hargreaves R, Brooks DJ. Reduced substance P binding in Parkinson's disease complicated by dyskinesias: an F-18-L829165 PET study. Neurology 2002; 58: A488-49.
96. Ramlackhansingh, AF.; Bose, SK.; Ahmed, I.; Turkheimer, FE.; Pavese, N.; Brooks, DJ. Adenosine A (2A) Receptor Availability in Parkinson's Disease Patients with and without Levodopa Induced Dyskinesias Studied with [C -11] SCH442416 PET. 62nd Annual Meeting of the American-Academy-of-Neurology 2010; 74: A588-A588.
97. Ahmed I, Bose SK, Pavese N, Ramlackhansingh A, Turkheimer F, Hotton G, Hammers A, Brooks DJ. Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias. Brain 2011; 134: 979-86.
98. Politis M, Wu K, Loane C, Kiferle L, Molloy S, Bain P, Brooks DJ, Piccini P: Serotonergic involvement in L-DOPA-induced dyskinesia [abstract]. Mov Disord 2010; 5: S658.
99. Wenning GK, Odin P, Morrish P, Rehncrona S, Widner H, Brundin P, Rothwell JC, Brown R, Gustavii B, Hagell P, Jahanshahi M, Sawle G, Björklund A, Brooks DJ, Marsden CD, Quinn NP, Lindvall O. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol 1997; 42: 95-107.
100. Piccini P, Lindvall O, Björklund A, Brundin P, Hagell P, Ceravolo R, Oertel W, Quinn N, Samuel M, Rehncrona S, Widner H, Brooks DJ. Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol 2000; 48: 689-95.
101. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S: Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001, 344:710-719.
102. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. A doubleblind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003; 54: 403-14.
103. Ma Y, Feigin A, Dhawan V, Fukuda M, Shi Q, Greene P, Breeze R, Fahn S, Freed C, Eidelberg D. Dyskinesia after fetal cell transplantation for Parkinsonism: a PET study. Ann Neurol 2002; 52: 628-34.
104. Hagell P, Piccini P, Björklund A, Brundin P, Rehncrona S, Widner H, Crabb L, Pavese N, Oertel WH, Quinn N, Brooks DJ, Lindvall O. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002; 5: 627-8.
105. Piccini P, Pavese N, Hagell P, Reimer J, Björklund A, Oertel WH, Quinn NP, Brooks DJ, Lindvall O. Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain 2005; 128: 2977-86.
106. Lang AE, Langston JW, Stoessl AJ, Brodsky M, Brooks DJ, Dhawan V, Elias WJ, Lozano AM, Moro E, Nutt JG, Stacy M, Turner D, Wooten GF. GDNF in treatment of Parkinson's disease: response to editorial. Lancet Neurol 2006; 5: 200-202
107. Politis M, Wu K, Loane C, Quinn NP, Brooks DJ, Rehncrona S, Bjorklund A, Lindvall O, Piccini P. Serotonergic Neurons Mediate Dyskinesia Side Effects in Parkinson's Patients with Neural Transplants. Sci Transl Med 2010; 2: 38-46.
108. Hilker R, Razai N, Ghaemi M, Weisenbach S, Rudolf J, Szelies B, Heiss WD. [18F]fluorodopa uptake in the upper brainstem measured with positron emission tomography correlates with decreased REM sleep duration in early Parkinson's disease. Clin Neurol Neurosurg 2003; 105: 262-9.
109. Herlofson K, Larsen JP. Measuring fatigue in patients with Parkinson's disease - the Fatigue Severity Scale. Eur J Neurol 2002; 9: 595-600.
110. Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, Houle S, Wilson AA, Meyer JH, Kish SJ. Elevated serotonin transporter binding in depressed patients with Parkinson's disease: a preliminary PET study with [11C] DASB. Mov Disord 2008; 23: 1776-1780.
111. Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, Piccini P. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010; 75: 1920-7.
112. Emre M. Dementia associated with Parkinson's disease. Lancet Neurol 2003; 2: 229-237.
113. Ito K, Nagano-Saito A, Kato T, Arahata Y, Nakamura A, Kawasumi Y, Hatano K, Abe Y, Yamada T, Kachi T, Brooks DJ. Striatal and extrastriatal dysfunction in Parkinson's disease with dementia: a 6-[18F] fluoro-L-dopa PET study. Brain 2002;125:1358-65
114. Goto I, Taniwaki T, Hosokawa S, Otsuka M, Ichiya Y, Ichimiya A. Positron emission tomographic (PET) studies in dementia. J Neurol Sci 1993; 114: 1-6.
115. Vander Borght T, Minoshima S, Giordani B, Foster NL, Frey KA, Berent S, Albin RL, Koeppe RA, Kuhl DE. Cerebral metabolic differences in Parkinson's and Alzheimer's diseases matched for dementia severity. J Nucl Med 1997; 38: 797-802.
116. Yong SW, Yoon JK, An YS, Lee PH. A comparison of cerebral glucose metabolism in Parkinson's disease, Parkinson's disease dementia and dementia with Lewy bodies. Eur J Neurol 2007;14:1357-62.
117. Hilker R, Thomas AV, Klein JC, Weisenbach S, Kalbe E, Burghaus L, Jacobs AH, Herholz K, Heiss WD. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology 2005; 65: 1716-1722.
118. Edison P, Rowe CC, Rinne JO, Ng S, Ahmed I, Kemppainen N, Villemagne VL, O'Keefe G, Någren K, Chaudhury KR, Masters CL, Brooks DJ. Amyloid load in Parkinson's disease dementia and Lewy body dementia measured with [11C]PIB positron emission tomography. J Neurol Neurosurg Psychiatry 2008; 79: 1331-1338.
119. Ballanger B, Strafella AP, van Eimeren T, Zurowski M, Rusjan PM, Houle S, Fox SH. Serotonin 2A receptors and visual hallucinations in Parkinson disease. Arch Neurol 2010; 67: 416-21.
120. Weintraub D, Koester J, Potenza MN, Siderowf AD, Stacy M, Voon V, Whetteckey J, Wunderlich GR, Lang AE. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67: 589-95.
121. O'Sullivan SS, Evans AH, Lees AJ. Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management. CNS Drugs 2009; 23: 157-70.
122. Evans AH, Pavese N, Lawrence AD, Tai YF, Appel S, Doder M, Brooks DJ, Lees AJ, Piccini P. Compulsive drug use linked to sensitized ventral striatal dopamine transmission. Ann Neurol 2006; 59: 852-8.
123. Berridge KC, Robinson TE, Aldridge JW. Dissecting components of reward: 'liking', 'wanting', and learning. Curr Opin Pharmacol 2009; 9: 65-73.
124. Steeves TD, Miyasaki J, Zurowski M, Lang AE, Pellecchia G, Van Eimeren T, Rusjan P, Houle S, Strafella AP. Increased striatal dopamine release in Parkinsonian patients with pathological gambling: a [11C] raclopride PET study. Brain 2009; 132: 1376-85.
125. Van Eimeren T, Pellecchia G, Cilia R, Ballanger B, Steeves TD, Houle S, Miyasaki JM, Zurowski M, Lang AE, Strafella AP. Drug-induced deactivation of inhibitory networks predicts pathological gambling in PD. Neurology 2010; 75: 1711-6.
126. Goldstein DS, Holmes C, Li ST, Bruce S, Metman LV, Cannon RO III. Cardiac sympathetic denervation in Parkinson disease. Ann Intern Med 2000; 133: 338-347.
127. Berding G, Schrader CH, Peschel T, van den Hoff J, Kolbe H, Meyer GJ, Dengler R, Knapp WH. [N-methyl 11C]meta-Hydroxyephedrine positron emission tomography in Parkinson's disease and multiple system atrophy. Eur J Nucl Med Mol Imaging 2003; 30: 127-31.
128. Kranick SM, Duda JE. Olfactory dysfunction in Parkinson's disease. Neurosignals. 2008; 16: 35-40.
129. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 2003; 24:197-211.
130. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis, Neuropathol. Appl. Neurobiol 2007; 33: 599-614.
131. Bohnen NI, Gedela S, Kuwabara H, Constantine GM, Mathis CA, Studenski SA, Moore RY. Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson's disease. J Neurol 2007; 254: 84-90.